Targeting AKT and CK2 represents a novel therapeutic strategy for SMO constitutive activation‐driven medulloblastoma

por Yao, Yue‐Liang, Wang, Yan‐Xia, Yang, Fei‐Cheng, Wang, Chuan, Mao, Min, Gai, Qu‐Jing, He, Jiang, Qin, Yan, Yao, Xiao‐Xue, Lan, Xi, Zhu, Jiang, Lu, Hui‐Min, Zeng, Hui, Yao, Xiao‐Hong, Bian, Xiu‐Wu, Wang, Yan
Publicado 2022

EPHA2 mediates PDGFA activity and functions together with PDGFRA as prognostic marker and therapeutic target in glioblastoma

por Gai, Qu-Jing, Fu, Zhen, He, Jiang, Mao, Min, Yao, Xiao-Xue, Qin, Yan, Lan, Xi, Zhang, Lin, Miao, Jing-Ya, Wang, Yan-Xia, Zhu, Jiang, Yang, Fei-Cheng, Lu, Hui-Min, Yan, Ze-Xuan, Chen, Fang-Lin, Shi, Yu, Ping, Yi-Fang, Cui, You-Hong, Zhang, Xia, Liu, Xindong, Yao, Xiao-Hong, Lv, Sheng-Qing, Bian, Xiu-Wu, Wang, Yan
Publicado 2022